For a young female (<40) with HR-/HER2+ cT1-2N1, ypT1aN0 s/p mastectomy with SLNB, would you offer PMRT?
Would you feel confident in omission for residual disease in the breast and only 1 LN removed during SLNB, which is the same node that was biopsied up front?
Answer from: Radiation Oncologist at Academic Institution
Thanks for the question. In the seminal PMRT randomized trials of patients treated with adjuvant systemic therapy, PMRT improved overall survival. B-51 was not designed to evaluate the non-inferiority of PMRT omission. Beyond being less conservatively designed to test for superiority of "RNI" with r...
Comments
Radiation Oncologist at Kings County Hospital Center Excellent rationale. I share a similar view with y...
Radiation Oncologist at Northeast Alabama Regional Medical Center "In summary, the available data suggests there is ...
Radiation Oncologist at Mayo Clinic, Rochester, MN Thanks Dr. @Scarbrough, I should have specified th...
Answer from: Radiation Oncologist at Academic Institution
I agree with Dr. @Mutter's points about patients undergoing mastectomy and SLNB being underrepresented on B-51 and therefore using caution when applying the conclusions of B51 to these patients.I would also use caution when interpreting ypN0 in this case. There is evidence that after neoadjuvant che...
Answer from: Radiation Oncologist at Community Practice
I would be very uncomfortable omitting radiotherapy in this patient.
The patient is young which is associated with higher locoregional recurrence rates. The B-51 follow-up is short and the patient had residual disease in the breast. I appreciate the excellent summary of Dr. @Mutter.
Had the patien...
Excellent rationale. I share a similar view with y...
"In summary, the available data suggests there is ...
Thanks Dr. @Scarbrough, I should have specified th...